Observational studyBMC microbiology2026
Prevalence, clinical characteristics, and antibiotic resistance of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Türkiye (2023-2025).
Observational study in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Rising Carbapenem MICs and Clinical Dose Optimization: Bridging Resistance Surveillance and Pharmacokinetic/Pharmacodynamic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular characterization of carbapenem resistance and hypervirulence determinants of Klebsiella pneumoniae circulating in a tertiary hospital in Cyprus.Molecular biology reports · 2026Article
- Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children.BMC infectious diseases · 2026Article
- Antimicrobial resistance and associated risk factors in urinary tract infections diagnosed in the emergency department: a retrospective observational study.BMC infectious diseases · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) represents a growing public health threat due to limited treatment options, high morbidity and mortality rates. This study aimed to investigate the prevalence, clinical characteristics, and antibiotic resistance profiles of CRKP isolates identified in a tertiary hospital in Türkiye between 2023 and 2025.
methodsA retrospective observational study was conducted using microbiological and clinical data collected from patients diagnosed with CRKP infections between January 2023 and April 2025. A total of 1588 CRKP isolates were retrospectively analyzed and compared with patient clinical data. Bacterial identification and antimicrobial susceptibility testing were performed using the BD Phoenix 100 M50 automated system (Becton Dickinson Company, USA), and results were interpreted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.
resultsAmong 2376 K. pneumoniae isolates, the overall CRKP prevalence was 66.8%. The annual carbapenem resistance rates were 64.9% in 2023, 69.4% in 2024, and 61.0% in 2025, respectively. Resistance rates among CRKP isolates were as follows: tigecycline 14.7%, colistin 23.0%, fosfomycin 47.6%, ceftazidime-avibactam 50.9%, and amikacin 66.8%. The prevalence of CRKP was significantly higher among inpatients (83.8%) compared to outpatients (26.8%). Of the CRKP-positive samples, 62.5% were collected from patients in intensive care units (ICUs), 12.2% from hematology, and 5.1% from oncology departments. Tracheal aspirates accounted for 43.5% of isolates, followed by urine samples at 25.8%.
conclusionsThe study revealed a notably high prevalence of CRKP with substantial resistance to most commonly used antibiotics. Among the tested antibiotics, tigecycline showed the lowest resistance rate, consistent with its limited usage profile. These findings underscore the urgent need for strengthened infection control measures and may guide more effective empirical treatment strategies for CRKP infections in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.